HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases

. 2016 Feb ; 11 (1) : 101-6.

Jazyk angličtina Země Francie Médium print

Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid26194363
Odkazy

PubMed 26194363
DOI 10.1007/s11523-015-0379-4
PII: 10.1007/s11523-015-0379-4
Knihovny.cz E-zdroje

Nanomedicine allows achievement of tumor-selective drug delivery because of the enhanced permeability and retention (EPR) effect of solid tumors. We report here the first clinical application of a new agent-HPMA copolymer-conjugated pirarubicin (P-THP)-with a molecular size of about 8 nm, or 38.5 kDa. A patient had advanced prostate cancer with multiple metastases in the lung, pelvis, femur, and perhaps the sacrum. In April 2013, this 60-year-old patient started treatment with leuprorelin and estradiol, which continued until July 2014, but the patient became refractory to this treatment. So the patient underwent proton beam radiotherapy targeted to the primary prostate cancer, and P-THP was administered for numerous metastatic tumor nodules concomitantly with radiotherapy. This combination therapy had remarkable results, with complete remission of multiple metastases in the lung and bone. The prostate-specific antigen (PSA) value was decreased from about 1000 ng/mL on April 30, 2013, to about 100 ng/mL on June 24, 2013, with hormone therapy, but rose again to 964.2 ng/mL and then to 1472 ng/mL in July 2013, during leuprorelin administration. P-THP treatment administered concomitantly with proton beam irradiation was started in August 2013. The PSA value was decreased to 102 ng/mL on August 26, 2013, and then to 0.971 ng/mL on October 8, 2013, and 0.277 ng/mL on January 15, 2015. The P-THP doses ranged from 30 to 75 mg of free THP equivalent/patient every 2-3 weeks without signs of serious toxicity, such as cardiovascular side effects or a reduction in quality of life. No evidence of relapse was found more than 20 months after P-THP administration. This case demonstrates the value of hydrazone-bonded polymeric drugs in multimodal therapy.

Zobrazit více v PubMed

J Clin Oncol. 2008 Jan 10;26(2):242-5 PubMed

J Control Release. 2011 Nov 7;155(3):367-75 PubMed

Cancer. 1984 Feb 1;53(3):406-10 PubMed

Cancer. 1992 Mar 15;69(6):1440-4 PubMed

Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49 PubMed

N Engl J Med. 2004 Oct 7;351(15):1513-20 PubMed

J Control Release. 2012 Dec 10;164(2):138-44 PubMed

Cancer Chemother Pharmacol. 2003 Jun;51(6):512-8 PubMed

Oncologist. 2011;16(3):366-77 PubMed

Cancer Sci. 2015 Mar;106(3):270-8 PubMed

Adv Drug Deliv Rev. 2013 Jan;65(1):71-9 PubMed

Clin Oncol (R Coll Radiol). 2014 Oct;26(10):e21-46 PubMed

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247 PubMed

Expert Opin Drug Deliv. 2015 Jan;12(1):53-64 PubMed

Adv Drug Deliv Rev. 2015 Aug 30;91:3-6 PubMed

Br J Cancer. 2008 Aug 5;99(3):392-7 PubMed

Eur Urol. 1995;27(4):301-5 PubMed

Br J Cancer. 2008 Sep 16;99(6):900-10 PubMed

Future Sci OA. 2015 Nov 01;1(3):FSO4 PubMed

Adv Drug Deliv Rev. 2010 Feb 17;62(2):150-66 PubMed

Surgery. 2015 Jul;158(1):236-47 PubMed

Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(3):53-71 PubMed

J Vasc Res. 2009;46(3):218-28 PubMed

Cancer Sci. 2009 Dec;100(12):2426-30 PubMed

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e25-31 PubMed

J Control Release. 2014 Jan 28;174:81-7 PubMed

Cancer Sci. 2010 Aug;101(8):1866-74 PubMed

BMC Cancer. 2006 May 02;6:112 PubMed

Najít záznam

Citační ukazatele

Možnosti archivace